Summary
Potentiation of the anticoagulant-effect of warfarin by amiodarone was studied in 30 patients. Thirteen received both drugs concurrently, and 17 received warfarin alone and the combination sequentially. Warfarin doses were adjusted to maintain the prothrombin time between 25–30% of control and its kinetics were compared to those in 20 control patients who received warfarin alone. Potentiation occurred in 28/30 patients, presenting as a 35%–65% reduction in the required dose of warfarin, and was correlated with the dose of amiodarone (r=0.77, p<0.01). The free warfarin fraction was not affected by amiodarone (1.8% vs 1.6% in the controls). Warfarin clearance was lower in amiodarone-treated patients than in the controls (1.4 vs 3.1 ml/min, p<0.01) with similar plasma concentrations (1.5 vs 1.2 µg/ml) despite administration of lower doses (23.3 vs 39 mg/week respectively). The amiodarone concentration was significantly correlated with the warfarin concentrations independent of the effect of amiodarone on the dose of warfarin. Amiodarone hat no effect on prothrombin other than through its actions on the dose and plasma concentration of warfarin. The mechanism of the amiodarone-warfarin interaction is pharmacokinetic through dose — and concentration — dependent inhibition of warfarin elimination.
Similar content being viewed by others
References
Simpson WT (1979) Amiodarone in cardiac arrhythmias. International Congress Series No. 16, Royal Society of Medicine. Grune and Stratton, New York, p 50
Martinowitz U, Rabinovich J, Goldfarb D, Many A, Bank H (1981) Interaction between warfarin sodium and amiodarone (letter). N Engl J Med 304: 671–672
Rees A, Dalal JJ, Reid PG, Henderson AH, Lewis MJ (1981) Dangers of amiodarone and anticoagulant treatment. Br Med J 282: 1756–1757
Serlin MJ, Sibeon RG, Green GJ (1981) Dangers of amiodarone and anticoagulant treatment (letter). Br Med J 283: 58
Hamer A, Peter T, Mandel WJ, Scheinman MM, Weiss D (1982) The potentiation of warfarin anticoagulation by aminodarone. Circulation 65: 1025–1029
Forman WB, Shales J (1978) Comparison of high-performance liquid chromatography and a spectrophotometric technique for determining plasma warfarin. J Chromatogr. 146: 522–526
Lesko LJ, Marion A, Canada AT, Haffajee C (1981) High pressure liquid chromatography of amiodarone in biological fluids. J Pharm Sci 70: 1366–1367
Rowland M, Tozer TN (1980) Clinical pharmacokinetics. Concepts and applications, Chapter 6. Hepatic clearance and elimination. Lea and Febiger, Philadelphia, p 60
Haffajee CI, Love JC, Alpert JS, Asdourian GK, Sloan KC (1983) Efficacy and safety of long term amiodarone in treatment of cardiac arrhythmias. Am Heart J 106: 935–943
Marcus FI (1983) Drug interactions with amiodarone. Am Heart J 106: 924–929
Shepard AMM, Hewick DS, Moreland TA, Stevenson IH (1977) Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol 4: 315–320
Yacobi A, Udall JA, Levy G (1976) Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect. Clin Pharmacol Ther 19: 552–558
Mungall D, Ludden TM, Marshall J, Crawford M, Hawkins D (1984) Relationships between steady-state warfarin concentrations and anticoagulant effect. Clin Pharmacokinet 9 [Suppl 1]: 99–100
Author information
Authors and Affiliations
Additional information
The study formed part of Dr. Shafran's, M. D., thesis at the Haifa University School of Medicine, Israel
Rights and permissions
About this article
Cite this article
Almog, S., Shafran, N., Halkin, H. et al. Mechanism of warfarin potentiation by amiodarone: Dose — and concentration — Dependent inhibition of warfarin elimination. Eur J Clin Pharmacol 28, 257–261 (1985). https://doi.org/10.1007/BF00543320
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00543320